Latanostad

Latanoprost, the active ingredient in Latanostad, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to treat primary open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Latanostad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanostad is a prostaglandin analog that reduces intra‑ocular pressure in glaucoma‑related conditions. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces elevated eye pressure to prevent conversion to glaucoma. - Secondary ocular hypertension (if prescribed): helps control pressure after ocular surgery or trauma.

Latanostad may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Increased iris pigmentation: darkening of the eye color. - Eyelash growth: longer, thicker lashes. - Conjunctival hyperemia: mild eye redness. - Eye irritation or foreign‑body sensation. - Periorbital skin darkening.

Serious or Rare Side Effects: - Uveitis or iritis: inflammation inside the eye. - Corneal edema: swelling of the cornea. - Severe allergic reaction: swelling, rash, or difficulty breathing. - Vision loss: sudden decrease in visual acuity. - Persistent eye pain or pressure. - Endophthalmitis: intra‑ocular infection (rare).

Before using Latanostad, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential exposure with a physician. - Pre‑existing eye conditions: inform the prescriber of uveitis, ocular infections, or corneal disease. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Systemic prostaglandin sensitivity: avoid if known hypersensitivity exists. - Store below 25°C: keep in the original container, protect from light and moisture.

Latanostad can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce efficacy. - Other prostaglandin analogues: concurrent use can increase side‑effect risk.

Moderate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: additive intra‑ocular pressure lowering effect. - Systemic carbonic anhydrase inhibitors: may enhance pressure reduction. - Anticholinergic eye drops: potential for altered ocular surface response.